Valuation : Quanterix Corporation

Market Cap 118M 102M 95.94M 87.4M 163M 11.3B 165M 1.14B 440M 5.73B 444M 434M 18.21B P/E 2026 *
-1.28x
P/E 2027 * -2.02x
Enterprise Value 118M 102M 95.94M 87.4M 163M 11.3B 165M 1.14B 440M 5.73B 444M 434M 18.21B EV / Sales 2026 *
0.82x
EV / Sales 2027 * 0.75x
Free-Float
93.67%
Yield 2026 *
-
Yield 2027 * -
1 day-5.66%
1 week-3.10%
Current month-6.37%
1 month+3.31%
3 months-18.57%
6 months-50.20%
Current year-60.69%
1 week 2.49
Extreme 2.49
2.83
1 month 2.43
Extreme 2.43
3.25
Current year 2.15
Extreme 2.15
8.77
1 year 2.15
Extreme 2.15
8.77
3 years 2.15
Extreme 2.15
29.7
5 years 2.15
Extreme 2.15
60.92
10 years 2.15
Extreme 2.15
92.57
Manager TitleAgeSince
Chief Executive Officer 59 2026-01-18
Director of Finance/CFO 50 2026-06-21
Chief Operating Officer - 2026-05-13
Director TitleAgeSince
Director/Board Member 63 2022-06-05
Chairman 64 2025-03-23
Director/Board Member 48 2024-08-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Exercice

Chief Technology Officer

366 0.0008%
8/19/26 Exercice

Director

7,910 0.0170%
8/17/26 Exercice

Chairman

5,604 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
-5.66%-3.10%-42.26%-89.81% 118M
-0.41%-2.47%+26.57%+16.38% 223B
-2.11%-4.98%+4.12%-19.26% 141B
+2.04%-2.53%-19.89%+20.87% 127B
-4.14%-8.20%-59.04%-19.99% 62.46B
+0.25%-1.23%-19.75%-14.89% 49.73B
+0.68%-3.35%+10.85%+17.15% 50.01B
-1.13%-4.57%+15.31%+25.55% 40.35B
-0.78%-2.88%+37.06%+52.38% 39.46B
-0.17%-4.19%-18.82%+48.42% 31.41B
Average -0.99%-3.65%-6.58%+3.68% 76.49B
Weighted average by Cap. -0.56%-3.34%+1.74%+9.25%

Financials

2026 *2027 *
Net sales 144M 124M 117M 106M 199M 13.75B 201M 1.39B 535M 6.97B 540M 528M 22.15B 158M 136M 128M 117M 219M 15.13B 221M 1.53B 589M 7.67B 594M 581M 24.37B
Net income -92.79M -79.8M -75.29M -68.59M -128M -8.87B -129M -897M -345M -4.5B -348M -341M -14.29B -70.09M -60.27M -56.87M -51.81M -96.85M -6.7B -97.73M -677M -261M -3.4B -263M -257M -10.8B
Net Debt - -
Logo Quanterix Corporation
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Employees
450
Date Price Change Volume
26-09-10 US$2.500 -5.66% 456,055
26-09-09 US$2.650 -2.93% 267,379
26-09-08 US$2.730 +1.49% 647,367
26-09-04 US$2.690 +4.26% 274,590
26-09-03 US$2.580 -1.15% 842,035
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
2.500USD
Average target price
3.000USD
Spread / Average Target
+20.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. QTRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!